F-18 PSMA-11 PET for Imaging and Staging of Hepatocellular carcinoma with Evaluation of Survival
Key facts
- Where
- Gent, BelgiumSee the site
- Phase
- 2. fázis
Where in Belgium
- Universitair Ziekenhuis GentGent, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Universitair Ziekenhuis Gent
- Trial code
- EU 2023-508709-26-00
- Record updated
- 2026. szeptember 30.
- Original description
To determine the diagnostic accuracy of F-18 PSMA-11 PET/CT for the (re)staging of hepatocellular carcinoma (HCC) compared to F-18 FDG PET/CT and F-18 Choline PET/CT.Read full original descriptionShow less
To determine the diagnostic accuracy of F-18 PSMA-11 PET/CT for the (re)staging of hepatocellular carcinoma (HCC) compared to F-18 FDG PET/CT and F-18 Choline PET/CT.
Inclusion: Willing and mentally legally capable to provide written informed consent; 18 years of age or older; One of the following clinical scenario’s: • New diagnosis of HCC, confirmed either by biopsy or imaging using EASL/AASLD criteria, with a high risk of metastases indicated by portal invasion or a primary lesion of >5cm diameter. • Known diagnosis of HCC that requires restaging due to unexplained elevated AFP tumor markers, known metastases, impending initiation of immunotherapy, or being on the waiting list for a liver transplant; Have either planned or recently undergone (within the past 4 weeks) both F-18 FDG PET/CT and F-18 Choline PET/CT scans as part of their diagnostic or staging workup for one of the above indications.
Exclusion: Known active malignancy other than hepatocellular carcinoma; History of prostate cancer; Active pregnancy; Possible pregnancy and refusal of urine pregnancy test.